Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
The 24th China International Fair for Investment & Trade concluded with fruitful results -- Investment Linking the World and Opening Up for a Win-Win Future
World-Class Marine Port Cluster Comprehensive Index 2024 Released - A New Benchmark of Innovation, Integration and Development for Global Port and Shipping Industry